Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 88, Issue 2, 2017, Pages 132-136

  Juryńczyk, Maciej ^a   Tackley, George ^a   Kong, Yazhuo ^a   Geraldes, Ruth ^a   Matthews, Lucy ^a   Woodhall, Mark ^a   Waters, Patrick ^a   Kuker, Wilhelm ^a   Craner, Matthew ^a   Weir, Andrew ^a   Deluca, Gabriele C ^a   Kremer, Stephane ^b,c   Leite, Maria Isabel ^a   Vincent, Angela ^a   Jacob, Anu ^d   De Sèze, Jérôme ^b,c   Palace, Jacqueline ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AQUAPORIN 4; AUTOANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BRAIN DAMAGE; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; DAWSON FINGER TYPE LESION; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOASSAY; INFERIOR TEMPORAL GYRUS; INTERRATER RELIABILITY; LATERAL BRAIN VENTRICLE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; U FIBER LESION; BRAIN; CLINICAL TRIAL; DIAGNOSTIC IMAGING; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEUROMYELITIS OPTICA; PATHOLOGY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AQUAPORIN 4; AUTOANTIBODIES; BRAIN; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84994626514     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2016-314005     Document Type: Article

References (19)

1. Palace J, Leite MI, Nairne A, et al. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. rch Neurol 2010;67:1016-17.
2. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-45.
3. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
4. Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015;72:81-7.
5. Juryńczyk M, Craner M, Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg sychiatr 2015;86:20-5.
6. Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013;80:1330-7.
7. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84:1165-73.
8. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-69.
9. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-71; discussion 669.
10. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89.
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
12. Juryńczyk M, Weinshenker B, Akman-Demir G, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol 2016;263:140-9.
13. Kitley J, Leite MI, Küker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 2013;70:1375-81.
14. Piccolo L, Woodhall M, Tackley G, et al. Isolated new onset 'atypical'optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. J Neurol 2016;263:370-9.
15. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-7.
16. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276-83.
17. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-81.
18. Kister I, Ge Y, Herbert J, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013;81:1966.
19. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.